New drug target for Hard-to-Treat cancers enters human testing

NCT ID NCT07223125

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times

Summary

This study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The goal is to find a safe dose and check for side effects. About 360 participants will take part in two phases: first to find the right dose, then to confirm safety at that dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED-STAGE SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32803, United States
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
NEXT Oncology
RECRUITING

Irving, Texas, 75039, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

ADVANCED-STAGE SOLID TUMORS